KOSDAQBiotech & Pharma061250

Hwail Pharm

₩5,160▼ 2.09%2026-11-18 close
Market Cap
₩43.4B
Turnover
₩14,174,730
Volume
2.7K
Shares out.
8.4M
PER
18.2×
PBR
0.2×
EPS
₩299
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Four Loss Quarters Amid a Control Transition

Revenue has fallen for three straight years and operating losses have persisted for four quarters, while a change of largest shareholder and new business objectives are moving forward at the same time.

  1. 1

    Revenue has declined for three consecutive years through 2025, and the company swung to an operating loss of KRW 2.28 billion in 2025.

  2. 2

    Operating losses have run for four quarters from Q4 2025 through Q3 2026, while Q2 2026 showed net income attributable to controlling shareholders of KRW 4.37 billion.

  3. 3

    A share sale disclosed on September 15, 2026 would shift the largest shareholder to a technology investment fund, with the remaining balance due on November 19, 2026.

  4. 4

    A November 5, 2026 disclosure put a proposal to add 23 new business objectives, including semiconductors, AI and resort operations, before an extraordinary shareholders meeting on November 20, 2026.

  5. 5

    Total equity was KRW 206.9 billion at the end of 2025 against total liabilities of KRW 6.29 billion, while net income attributable to controlling shareholders over the last four quarters totals only KRW 2.51 billion.

02

Business structure

Hwail Pharm is a active pharmaceutical ingredient maker founded in 1980 and listed on KOSDAQ in 2002. Built on more than 40 years of organic synthesis expertise, it develops and produces raw materials used across respiratory, cardiovascular and digestive therapeutic areas.

Production rests on a cGMP-certified facility in Hwaseong, Gyeonggi, and the company describes a portfolio of about 200 products. It supplies raw materials to roughly 300 domestic pharmaceutical companies and is expanding exports to Japan and Europe.

In 2005 it acquired a cephalosporin antibiotic plant, and it has also run a functional food ingredient business using nano-emulsion technology. Recently it has been diversifying by splitting operations into a food ingredient unit, including coenzyme Q10, and an antibiotic unit.

As of the third quarter of 2020, cough suppressants accounted for about 7 percent of total revenue and were the largest share among key products, according to contemporaneous press coverage. Raw material earnings depend on the production plans and drug approval timing of customer pharmaceutical companies.

Competitive differentiation rests on cGMP facilities, synthesis capability and long-term customer relationships. As of November 2026, the business direction is widening through the addition of new business objectives beyond the core raw materials.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩24.3B₩200M0.7%
2025Q4₩18.6B-₩1.3B−7.0%
2026Q1₩23.4B-₩600M−2.4%
2026Q2₩24.5B-₩900M−3.7%
2026Q3₩24B-₩800M−3.3%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩132.1B₩4.8B-₩6.3B3.6%−3.6%5.7%
2023₩122.5B₩2B₩3.9B1.7%2.2%6.6%
2024₩119.8B₩800M₩6.5B0.6%3.2%6.0%
2025₩100.8B-₩2.3B-₩200M−2.3%−0.1%3.0%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-14

04

Earnings analysis

Annual revenue fell from KRW 132.1 billion in 2022 to KRW 122.5 billion in 2023 (down 7.2% year on year), KRW 119.8 billion in 2024 (down 2.3%) and KRW 100.8 billion in 2025 (down 15.8%).

Revenue declined for three consecutive years from 2023 to 2025, with 2022 the largest year and 2025 the smallest in the 2022–2025 period. Daily Pharm also reported that revenue has fallen for three straight years from a 2022 peak.

Operating profit dropped from KRW 4.77 billion in 2022 to KRW 2.05 billion in 2023 (down 57.1%) and KRW 755 million in 2024 (down 63.1%), before turning into an operating loss of KRW 2.28 billion in 2025.

Operating margin went from 3.6 percent in 2022 to 1.7 percent in 2023, 0.6 percent in 2024 and -2.3 percent in 2025.

Net income attributable to controlling shareholders swung from a loss of KRW 6.33 billion in 2022 to a profit of KRW 3.86 billion in 2023, rose to KRW 6.48 billion in 2024 (up 67.8%), and then fell back into a loss of KRW 233 million in 2025. Net income including non-controlling interests followed the same pattern.

The company attributes the 2025 loss partly to lower output and higher costs following the 2022 Sangsin-ri plant fire. Operating cash flow moved from -KRW 234 million in 2022 to KRW 7.02 billion in 2023, KRW 11.6 billion in 2024 and KRW 11.9 billion in 2025.

Total equity at the end of 2025 was KRW 206.9 billion, all attributable to controlling shareholders, against total liabilities of KRW 6.29 billion, a debt ratio of 3.0 percent.

Quarterly revenue went from KRW 24.3 billion in Q3 2025 to KRW 18.6 billion in Q4 2025 (down 23.6% quarter on quarter), then KRW 23.4 billion in Q1 2026 (up 26.3%), KRW 24.5 billion in Q2 (up 4.4%) and KRW 24 billion in Q3 2026 (down 1.9% quarter on quarter and down 1.3% year on year).

Quarterly operating results moved from an operating profit of KRW 165 million in Q3 2025 to an operating loss of KRW 1.3 billion in Q4 2025, and losses have continued through Q3 2026, four quarters in a row.

The operating losses were KRW 566 million in Q1 2026, KRW 912 million in Q2 (wider) and KRW 781 million in Q3 (narrower, a swing to loss from a year earlier).

Net income attributable to controlling shareholders was KRW 4.37 billion in Q2 2026, up 655.5% from the prior quarter, before a net loss of KRW 1.93 billion in Q3 2026. The divergence between an operating loss and positive net income in Q2 makes non-operating items and one-off factors the next point to check. Net income attributable to controlling shareholders over the last four quarters totals KRW 2.51 billion.

05

Industry analysis

The raw materials market is sensitive to drug pricing policy at finished-drug makers and to exchange rate movements. In April 2026 Daily Pharm reported that raw material suppliers' earnings deteriorated together and pointed to drug price revisions and a strong dollar as background.

Hwail Pharm's revenue decline can be read as the combined effect of these industry factors and the 2022 fire that the company cites. Based on disclosed figures alone, it is difficult to separate how much each factor contributed.

On the customer side, relationships with about 300 domestic pharmaceutical companies are cited as a strength. Exports to Japan and Europe are affected by local regulation and currency movements.

A raw material supplier does not set the price of finished products, so it is exposed to procurement policy changes at its customers. Compared with innovative drug developers in the same bio and pharma sector, its R&D scale and earnings structure differ.

The newly added business objectives in semiconductors, AI and tourism have no direct link to the raw materials market. Whether the industry is recovering can be tracked through revenue trends in the raw materials segment and the operating margin.

06

Outlook

The share sale was disclosed on September 15, 2026. Two existing shareholders agreed to sell 2,343,750 shares, a 27.84 percent stake, to a technology investment fund for KRW 75 billion. A deposit of KRW 20 billion has been paid, and the remaining KRW 55 billion is due on November 19, 2026.

The fund becomes the largest shareholder once the balance is paid and shares are transferred. On the same timeline, the company decided on a third-party rights offering of about KRW 10 billion and a convertible bond issue of about KRW 10 billion, both disclosed as operating funds.

In a November 5, 2026 disclosure, the company proposed adding 23 business objectives to its articles, including semiconductor elements, AI data services, hot spring and spa operations, and hotel and resort operations.

These proposals will be voted on at an extraordinary shareholders meeting in Pyeongtaek on November 20, 2026, alongside the election of four directors and one standing auditor. According to InfoStock Daily, cash and financial assets on a standalone basis at the end of the first half of 2026 totaled KRW 92.7 billion.

In the same report, the company said it had not received any plan for using funds after the change of control. The next periodic report is the 2026 annual report, which will include fourth-quarter operating results. Follow-up proceedings may continue after the first-instance ruling on the 2022 fire case on May 28, 2026.

07

Valuation

PER
18.2×
PBR
0.2×
ROE
1.2%
EPS
₩299
BPS
₩25,042
Dividend per share
₩0

Market capitalization sits below the total equity of KRW 206.9 billion reported at the end of 2025, so the shares trade at a discount to book value.

While operating losses continue, earnings-based multiples change substantially depending on the period chosen, so comparison against net asset value gives the more reliable factual reference.

Net income attributable to controlling shareholders over the last four quarters totals KRW 2.51 billion, and that window includes losses in Q4 2025 and Q3 2026. No dividend flow is currently visible, so shareholder return on that basis is minimal.

The KRW 75 billion paid in the September 2026 share sale is a control transaction value and differs in nature from the price formed in the market. The current valuation picture combines a discount to net asset value with continuing losses.

Any comparison with past trading ranges has to reflect changes in equity size and earnings structure over the same period.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-14

08

Bull factors

Balance sheet capacity

Cash and financial assets on a standalone basis at the end of the first half of 2026 were reported at KRW 92.7 billion. Operating cash flow stayed positive, at KRW 7.02 billion in 2023, KRW 11.6 billion in 2024 and KRW 11.9 billion in 2025. This resource base could support both a core business recovery and new investments.

Quarterly earnings direction turns

Net income attributable to controlling shareholders was KRW 579 million in Q1 2026, a swing back to profit from a net loss in Q4 2025. It reached KRW 4.37 billion in Q2 2026, up 655.5% from the prior quarter. Quarterly revenue held between KRW 23.4 billion and KRW 24.5 billion from Q1 to Q3 2026. The operating loss narrowed to KRW 781 million in Q3 2026 from KRW 912 million in Q2.

Supplier base and production assets

The company says it supplies raw materials to about 300 domestic pharmaceutical companies and has a portfolio of about 200 products. It is expanding exports to Japan and Europe.

Its cGMP-certified facility in Hwaseong and more than 40 years of organic synthesis expertise are assets that would underpin any core business recovery. Long-term relationships with customer pharmaceutical companies are cited as a basis for order stability.

09

Bear factors

Continued margin decline

Operating margin fell from 3.6 percent in 2022 to 1.7 percent in 2023, 0.6 percent in 2024 and -2.3 percent in 2025. The 2025 operating loss of KRW 2.28 billion marked a swing from profit. Q3 2026 still showed an operating loss of KRW 781 million, a swing to loss from a year earlier.

Four consecutive quarters of operating losses mean a recovery in core profitability has not yet appeared in the reported numbers.

Shrinking revenue base

Revenue fell from KRW 132.1 billion in 2022 to KRW 100.8 billion in 2025. Q3 2026 revenue of KRW 24 billion was down 1.3 percent from a year earlier. Quarterly revenue in 2026 has stayed between KRW 23.4 billion and KRW 24.5 billion, well below the 2022 annual pace.

Whether the decline reflects weaker demand or production constraints needs to be separated using segment-level data.

Uncertainty over control and direction

Completion of the share transfer, with the remaining balance due November 19, 2026, leaves the control structure unsettled until closing. The 23 new business objectives in semiconductors, AI and tourism are far from the core raw materials business.

The company said it had not received any investment plan for funds after the change of control. Uncertainty over direction and use of funds will persist until disclosures give more detail.

10

Risk factors

Production safety and legal risk

A 2022 fire at the Sangsin-ri plant killed one person and injured more than ten. Production was halted in October 2022 and partially resumed in March 2023. On May 28, 2026 the first-instance court sentenced the former CEO to two years in prison, suspended for three years, and fined the company KRW 200 million. The company cites the 2022 fire as a factor in the 2025 loss.

Dilution and funding

In September 2026 the company decided on a third-party rights offering of about KRW 10 billion and a convertible bond issue of about KRW 10 billion, both for operating funds.

A bond investment firm acquired 1,205,690 convertible bonds on October 8, 2026, raising its holding ratio to 12.53 percent, as disclosed on November 2, 2026. Conversion would increase the number of shares outstanding.

Control transition and business expansion

Daily Pharm reported that the largest shareholder is changing for the fourth time in about five years. The investor fund's main contributor is Dynamic Solution, and a separate investment firm operates the fund.

The new business objectives disclosed on November 5, 2026 cover semiconductors, AI and resorts, which are far from raw materials. With both the controlling party and the business direction changing, uncertainty over management continuity remains.

11

What to watch next

  1. November 19, 2026

    Payment of the KRW 55 billion remaining balance and completion of the share transfer. Once completed, the technology investment fund becomes the largest shareholder, which marks the final step of the change of control.

  2. November 20, 2026

    Voting results at the Pyeongtaek extraordinary shareholders meeting on the articles amendment adding 23 business objectives and the election of directors and an auditor. This is the first formal point at which the expansion of business objectives can be tested against actual business plans.

  3. Around late March 2027

    Filing of the 2026 annual report, which will disclose fourth-quarter operating results, full-year revenue, operating margin and operating cash flow. It is the point at which the operating loss trend since 2025 can be checked on a full-year basis.

  4. Around mid-May 2027

    The Q1 2027 quarterly report, which will show whether the operating losses running since Q4 2026 turn around and whether operating results and net income diverge in direction as they did in Q2 2026.

12

Overall view

Hwail Pharm is a raw materials supplier whose revenue fell from KRW 132.1 billion in 2022 to KRW 100.8 billion in 2025, and which swung to an operating loss of KRW 2.28 billion in 2025.

Quarterly revenue held between KRW 23.4 billion and KRW 24.5 billion through 2026, but operating losses have continued for four quarters. Net income attributable to controlling shareholders of KRW 4.37 billion in Q2 2026 marked a quarter back in profit, but Q3 2026 returned to a net loss of KRW 1.93 billion.

The balance sheet is strong, with total equity of KRW 206.9 billion against total liabilities of KRW 6.29 billion. Earnings power is limited, however, with net income attributable to controlling shareholders over the last four quarters totaling KRW 2.51 billion.

On the governance side, the balance payment on November 19, 2026 and the extraordinary shareholders meeting on November 20, 2026 are the next points to track.

The 23 new business objectives are far from the core business, and they can be read either as a source of added uncertainty or as an attempt to diversify revenue. The 2026 annual report, which will show full-year operating margin and fourth-quarter operating trends, will clarify the direction since 2025.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. jobkorea.co.kr
  2. saramin.co.kr
  3. newsthevoice.com
  4. app.rndcircle.io
  5. news.nate.com
  6. edaily.co.kr
  7. goinsider.kr
  8. infostockdaily.co.kr
  9. kormedi.com
  10. yakup.com
  11. news.nate.com
  12. news.nate.com
  13. dailypharm.com
  14. news.nate.com
  15. m.news.nate.com
  16. topstarnews.net
  17. m.news.nate.com
  18. imnews.imbc.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis